NINDS Cooperative Program in Translational Research Small Business Awards (U44)

The summary for the NINDS Cooperative Program in Translational Research Small Business Awards (U44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NINDS Cooperative Program in Translational Research Small Business Awards (U44): The goal of this funding opportunity announcement (FOA) is to support preclinical development and testing of new therapies for neurological disorders. The program will facilitate encouragementation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. Phase II and Fast-Track SBIR cooperative agreements are supported under the program. Phase I, as part of a Fast-Track, supports preliminary steps in the process for the preclinical development of therapeutics. To be eligible for Phase II support, either based on a previously successful Phase I or as part of a Fast-Track, projects must include therapeutic leads and in vivo proof of concept on efficacy. Phase II supports preclinical optimization and testing of the leads, and projects must be sufficiently advanced that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of the project period. Phase II cannot support early-stage therapeutic discovery activities such as screening. The program scope excludes clinical research, basic research, and studies of disease mechanism. The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. This is a milestone-driven SBIR cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress.

Federal Grant Title:	NINDS Cooperative Program in Translational Research Small Business Awards (U44)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-11-296
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.853
CFDA Descriptions:	Extramural Research Programs in the Neurosciences and Neurological Disorders
Current Application Deadline:	Jan 07, 2013
Original Application Deadline:	Sep 07, 2012
Posted Date:	Aug 08, 2011
Creation Date:	Apr 10, 2012
Archive Date:	Feb 07, 2013
Total Program Funding:
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria: 1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; 2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there can be no more than 49 percent participation by foreign business entities in the joint venture; 3. Is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or it must be a for-profit business concern that is at least 51 percent owned and controlled by another for-profit business concern that is at least 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, except in the case of a joint venture, where each entity to the venture must be 51 percent owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States; and; 4. Has, including its affiliates, not more than 500 employees.
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...; • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...; • NINDS Program Project Grant (P01 Clinical Trial Optional); • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...